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The report of the Assessment of Ms TANZIMA NUHAT SHARNA's Dissertation Defense 
 
論文の要旨 
Abstract of thesis 
 
Research 1: Droplet digital PCR assay for RHOA mutation detection in angioimmunoblastic T-cell 
lymphoma 
 
Purpose: Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of nodal peripheral T-cell 
lymphoma (PTCL). In addition, a part of peripheral T-cell lymphoma not otherwise specified 
(PTCL-NOS), referred to nodal PTCL with TFH phenotype, share similar genetic features of AITL. 
The hotspot mutation is the G17V RHOA mutations, which are observed in approximately 60% of the 
cases. Routine detection of the G17V RHOA mutations is troublesome because tumor contents are 
low in clinical specimen. In addition, quality of genomic DNAs derived from biopsy specimens is 
relatively poor. Therefore, the author tried to establish a sensitive method to detect G17V RHOA 
mutations in clinical samples.  
Methods: The author analyzed 67 PTCL (40 AITL and 27 PTCL-NOS) patient samples by droplet 
digital PCR (ddPCR). A 20 μl reaction mixture containing 10 μl of ddPCR supermix specific for the 
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G17V RHOA mutation and 40 ng of DNA template was mixed with 70 μl of droplet generation oil by 
using QX200 Droplet Generator. The water-in-oil droplets in a 96-well PCR plate were placed on a 
thermocycler for PCR amplification, and then were read by Droplet Reader using QuantaSoft 
software. For PNA-LNA PCR clamp, PCR primers, fluorogenic probes, and a PNA clamp primer and 
DNA template were added to the Premix Ex taq (Probe qPCR) Master Mix. Total probe (fluorescent 
dye Cy5) targeted normal sequences and LNA probe (fluorescent dye FAM) targeted the sequences 
with the G17V mutation. Quantitative polymerase chain reaction was then performed. The results of 
ddPCR and PNA-LNA clamp were compared with those of next generation sequencing (NGS). 
Results: Initially, the lower limits of detection (LOD) and quantification (LOQ) for ddPCR were 
established with serial dilution samples of the G17V mutation at 13%, 3.25%, 0.81%, 0.20%, 0.05%, 
0.01%, and 0.0025%. The LOQ of ddPCR was determined as 0.05%, and that of the PNA-LNA PCR 
clamp method was 0.01%. Totally, c.50G>T, p.Gly17Val mutation was identified in 31 of 67 (46.3%) 
PTCL samples (AITL 23/40 [57.5%] and PTCL-NOS 8/27 [29.6%]). Both ddPCR and PNA-LNA clamp 
assays detected the mutation in all 31 of 67 samples. The sensitivity of ddPCR and PNA-LNA clamp 
assays for detection of c.50G>T, p.Gly17Val mutation was 100% (31/31) with 100% (36/36) specificity, 
while NGS had 87% (27/31) sensitivity with 100% (36/36) specificity. Three other RHOA mutations 
(p.Gly17Val, p.Gly17Leu, and p.Gly17Glu) were detected by NGS, but they could not be detected by 
either of the ddPCR or PNA-LNA clamp assay. Variant allele frequencies by ddPCR and those by 
NGS showed high concordance (p<0.001). 
Conclusion: The author concluded the ddPCR and PNA-LNA clamp assays were more sensitive to 
detect low frequency G17V RHOA mutations than NGS in AITL tissue samples, although NGS was 
convenient for detection of all mutational types. A combination of ddPCR or PNA-LNA clamp method 
and NGS was required for exact diagnosis of AITL. 
 
Research 2: Analysis of control region of mitochondrial DNA in samples of diffuse large B-cell 
lymphoma. 
 
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malignancy among 
adult population. Due to the involvement of multiple oncogenic pathways a wide variety of genetic 
lesions in the nuclear genome have been identified as causative agents in DLBCL. There are, 
however, few studies of mitochondrial genome (mtDNA) in the pathogenesis of DLBCL.  The human 
mtDNA is a small circular, double stranded (outer heavy strand, and inner light strand), 16.6kb 
molecule which contains 37 genes encoding 13 subunits of respiratory chain complexes, 22tRNAs 
and 2 ribosomal RNAs.  Each mitochondrion contains an average of 2 to 10 copies of mtDNA. Tumor 
derived mutant mtDNA can serve as a predictive biomarker, because, mitochondrial D-loop region is 
known as a hotspot for mutations and control region (CR) controls mitochondrial transcription and 
replication process. The purpose of this study was to evaluate the mutation frequency in the CR of 
mtDNA in DLBCL samples. 
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Methods: The author collected archived fresh frozen paraffin embedded (FFPE) samples from tumor 
biopsy of 20 DLBCL patients with matched normal bone marrow (BM) samples from 14 patients. 
DNAs were extracted from FFPE samples using QIAamp FFPE tissue Kit and from BM samples 
using and QIAamp DNA Blood Mini Kit. Amplification reactions were carried out with 20 ng of 
extracted DNA as the template and 300 nM concentration of ten pairs of forword and reverse primers 
in a 10 μl reaction volume with Kod-Plus-Neo PCR reagent. To prepare DNA libraries for NGS, PCR 
amplicons were ligated to barcode adapters and P1 adapters, and amplified using an IonPGM 
fragment library preparation kit. Libraries were then subjected to deep sequencing on the Ion 
Torrent PGM platform for 300 base-pair single-end reads. Sequencing data were analyzed using 
Variant Caller 5.0.   
Results: Somatic single nucleotide variants were found in two of 14 (14%) tumor samples in the CR of 
mtDNA. They were m.150C>T (allele frequency [AF] 24.5%), m.152T>C (AF 21.2%), m.189A>G (AF 
5.5%), m.194 C>T (AF 8.8%), m.195T>C (AF 15.2%), m.199T>C (AF 10.7%), and m.16129G>A (AF 
32.6%) in a patient, and m.235A>G in another patient. These mutations were absent in the paired 
normal bone marrow samples.   
In addition, the author found four heteroplasmic mutations in both tumor and paired BM samples 
out of total 14 samples. Among them two site-specific heteroplasmic mutations were present at 
m.16093T>C in a patient (tumor AF 14.1% and BM AF 86%) and another (tumor AF 2.6% and BM 
AF 11.2%). This site is known to be a common site of tissue-specific heteroplasmy. The other two 
heteroplasmic mutations were mtDNA sequence variants.  
Conclusion: The author showed that disease-specific somatic mutations were noted in mtDNA of 
DLBCL patients. For studying the molecular mechanism of DLBCL, mtDNA can be considered as a 
potential target to detect mutations other than genomic DNA. 
 
審査の要旨 
Abstract of assessment result 
【批評 Review】 
This dissertation is comprised of two studies. In the first study, “Droplet digital PCR assay for RHOA 
mutation detection in AITL”, the applicant clearly showed ddPCR was more sensitive than NGS to 
detect the G17V RHOA mutations in patients with AITL. Because tumor cell contents in biopsy 
specimens from these patients are quite low, the results of this study are important to make a 
diagnosis of AITL in the clinical setting. The second study, “Analysis of control region of 
mitochondrial DNA in samples of DLBCL, is challenging and attractive, because thus far there have 
been few studies on mutations of mtDNA in DLBCL using whole genome sequencing. This study 
raised new questions to be addressed in future studies. For example, a key feature of the mtDNA is 
its high copy number in cells (10–10,000 copies), and mutated mtDNA is in the state of heteroplasmy, 
coexistence with wild type mtDNA. Thus, dysfunction of mitochondria and cellular consequence 
depend on the percentage of mutated allele as well as the site of mutation. The threshold of the 
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percentage of heteroplasmy and function of the mutated mitochondrial gene are good subjects for 
future experiments.    
【最終試験の結果 Assessment】 
The final examination committee conducted a meeting as a final examination on 18 June, 2018. The 
applicant provided an overview of dissertation, addressed questions and comments raised during 
Q&A session. All of the committee members reached a final decision that the applicant has passed 
the final examination.  
【結論 Conclusion】 
The final examination committee approved that the applicant is qualified to be awarded Doctor of 
Philosophy in Medical Sciences. 
 
 
